AKBA · Akebia Therapeutics, Inc. · Stock research

Current Thesis

The leg an investor was buying in July — independent outcomes data (VOICE, 2026-06-30) converting Vafseo into a protocol-preferred anemia agent inside the large dialysis organizations — did not survive the Q2 print. On 2026-08-05 Akebia beat on both lines (EPS -$0.03 vs -$0.04 consensus; revenue $49.128M vs $48.861M consensus) and simultaneously told the market that 2027 revenues are expected to decrease because Vafseo's price will be reset toward ESA price ranges once the TDAPA period ends on 2026-12-31. Management also put meaningful DaVita adoption at late 2026 or 2027, moving the one named upside catalyst to the right. Leerink cut to Market Perform with a $1.00 price objective on 2026-08-08. The 2026-08-14 close of $0.87 is -73.5% from the $3.29 52-week high, with a 3-month return of -17.7% and RSI(14) at 21.4. The narrative is dead — dated by the 2026-08-05 guide-down in kind and the 2026-08-08 downgrade, after a positive 2026-06-30 readout that produced no re-rate. That label describes the narrative, not the balance sheet: $155.5M of cash and a product line growing 34% quarter-on-quarter is a live company with a broken story.

Bullish and bearish views on Akebia Therapeutics, Inc.

The model's bull view on Akebia Therapeutics, Inc. (AKBA), in brief: Vafseo net product revenue $21.3M in Q2 2026 versus $15.8M in Q1 2026 (+34%, company-stated) and $13.3M in Q2 2025 — the ramp itself did not break (Q2 release, 2026-08-05). The bear view: The company itself guided the 2027 top line lower: on the 2026-08-05 call management said 2027 revenues are expected to decrease on the lower planned price, aligning Vafseo with ESA price ranges that are significantly below current pricing, after TDAPA ends 2026-12-31. Both cases follow in full.

Bull Case

• Vafseo net product revenue $21.3M in Q2 2026 versus $15.8M in Q1 2026 (+34%, company-stated) and $13.3M in Q2 2025 — the ramp itself did not break (Q2 release, 2026-08-05).
• Active patients above 10,500 at Q2, +41% from end-Q1; prescribers ~1,200, +17% quarter-on-quarter. The prescriber base is widening, not just deepening (Q2 release, 2026-08-05).
• VOICE interim (announced 2026-06-30, n=2,116): win odds 1.16 (95% CI 1.06–1.28, p=0.0016) on the mortality-plus-hospitalization composite, hospitalization IRR 0.90. The full dataset is still unpresented — the company points to "an upcoming medical meeting," and ASN Kidney Week runs 2026-10-21 to 2026-10-25 in Denver.
• Cash and equivalents $155.5M at 2026-06-30, with management stating resources fund the operating plan for at least two years.
• Second shot on goal opened 2026-08-03: an open-label Phase 2 basket trial of ebribafusp in IgA nephropathy, lupus nephritis and C3 glomerulopathy, up to 30 patients on weekly subcutaneous dosing, initial data expected in 2027.
• Sell-side dispersion is extreme: HC Wainwright Buy, $6 target (2026-07-01) against Leerink Market Perform, $1.00 (2026-08-08). A wide spread of targets around an $0.87 close means the outcome distribution is genuinely unresolved.

Bear Case

• The company itself guided the 2027 top line lower: on the 2026-08-05 call management said 2027 revenues are expected to decrease on the lower planned price, aligning Vafseo with ESA price ranges that are significantly below current pricing, after TDAPA ends 2026-12-31. Volume growth now has to outrun a price cut the company has already conceded.
• DaVita — flagged in July as the swing factor — was pushed to "late 2026 or 2027" for meaningful adoption (Q2 call, 2026-08-05).
• Legacy erosion is outrunning the ramp: Auryxia $25.5M in Q2 2026 versus $47.2M in Q2 2025; total revenue $49.1M versus $62.5M. Net loss $8.9M against net income of $0.2M a year earlier.
• The runway statement is financing-contingent: management's two-year language includes "a plan to refinance its senior secured term loan facility."
• With the close at $0.87 (2026-08-14), Nasdaq's $1.00 minimum bid standard becomes live arithmetic; a deficiency notice follows 30 consecutive business days below $1.00.
• The level named in the prior published note — a weekly close below $1.15 — was lost in the first week of August. The structure that framed the post-VOICE base is gone.

Setup & Price Structure

Reference close 2026-08-14: $0.87. Distance from the $3.29 52-week high: -73.5%. Three-month return -17.7%. RSI(14) 21.4 — deeply oversold, which describes velocity, not a reversal; there is no rising moving average anywhere near price to measure extension against, because price sits beneath a declining structure. The $1.00 round number now sits overhead and coincides with Leerink's target, making it the first meaningful supply shelf. The prior 52-week range published through July put the low near $0.82; the tape is now within a few cents of it. Evidence of a base would be weekly closes holding above the August low with expanding volume, then a reclaim through $1.15–$1.20 — the shelf lost after the print.

Positioning observables rather than verdicts: no dated company catalyst falls inside the next 30 days, so there is nothing scheduled to force a bid; the recent filing window shows no Form 4 activity, so there is no insider accumulation to cite either way; sell-side coverage moved to the low end on 2026-08-08 rather than clustering into strength. This is a name with thin new attention, not a crowded one.

Catalyst Calendar (next 30 days)

• None dated through 2026-09-15. Q2 was reported 2026-08-05; the next scheduled company event is outside the window. Any move in this period is flow, not event.
• ~2026-09-16 (est., conditional): if closes have been below $1.00 continuously since the 2026-08-05 print, the 30-consecutive-business-day Nasdaq minimum-bid clock would run out around mid-to-late September. This is inferred arithmetic from the listing standard, not a disclosed date; the observable is a deficiency notice, which the company would disclose.
• 2026-10-21 to 2026-10-25: ASN Kidney Week, Denver — the plausible venue for the full VOICE dataset the company has committed to present at "an upcoming medical meeting." No presentation has been confirmed.
• ~2026-11-05 (est.): Q3 2026 print, based on the 2026-05-07 and 2026-08-05 cadence.
• 2026-12-31: TDAPA period ends; the Vafseo price reset takes effect.

What Would Change Our Mind

The structure that would have to appear first is a dated commitment from a large dialysis organization — a protocol adoption at DaVita or a named LDO conversion disclosed with a start date rather than a 2027 aspiration. Second, a disclosed 2027 Vafseo pricing and volume framework at the Q3 print (~2026-11-05, est.) that shows unit growth more than offsetting the ESA-aligned price, which is the arithmetic the 2026-08-05 call left open. Third, full VOICE data presented at ASN Kidney Week (2026-10-21 to 2026-10-25) accompanied by a label or guideline pathway with a timeline, since the interim release carried neither.

On the downside, the gradeable condition: a weekly close below $0.80 takes out the $0.82-area low that framed the 52-week range through July 2026 and confirms the post-VOICE narrative failed outright rather than merely stalled. An equity raise or amended credit agreement disclosed before the refinancing is completed would break the runway claim independently of price. Conversely, sustained weekly closes back above $1.20 on expanding volume would argue the August capitulation overshot and the label needs revisiting.

Correlation Notes

• Single-asset renal pharma with a micro-cap float: moves on company-specific headlines far more than on XBI or broad biotech beta. The 2026-06-30 VOICE release and the 2026-08-05 print were both single-name events.
• Reimbursement-linked to the dialysis complex: the TDAPA-to-bundle transition is set by CMS ESRD PPS rulemaking, so policy headlines that move dialysis operators (DVA, FMS) also reprice the 2027 Vafseo assumption here, in the opposite direction — a lower bundled add-on is a cost saving for the operator and a revenue cut for the manufacturer.
• Auryxia's decline tracks generic ferric citrate supply, not Vafseo execution; the two lines can diverge inside the same quarter, as they did in Q2 2026 ($25.5M versus $21.3M).
• Below $1.00, the name trades with the micro-cap financing complex — dilution and listing-compliance flows dominate fundamental news on any given day.